Skip to content

The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries

The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07475156
Enrollment
100
Registered
2026-03-16
Start date
2025-08-01
Completion date
2026-02-01
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Delerium

Keywords

Post operative delerium, Dexmedetomidine, Melatonin, Open brain surgery, Combination

Brief summary

The aim of this study is to illuminate the effect of combination of dexmedetomidine and oral melatonin versus the use of dexmedetomidine infusion alone on the improving of post-operative delirium (POD) on patients undergoing open brain surgeries.

Detailed description

Study Population: Patients undergoing open brain surgeries will be randomly assigned into one of the following groups using computer generated codes and opaque sealed envelopes: 1. Group A will receive Dexmedetomidine IV Infusion at rate of (0.5 μg/kg/hr) in addition to oral placebo tablets. 2. Group B will receive Dexmedetomidine IV Infusion at rate of (0.5 μg/kg/hr) in addition to oral Melatonin (3 mg/tablet). * Study Procedures: A. Preoperative settings: All patients will be assessed preoperatively by careful history taking, full physical examination, and laboratory evaluation. B. Intraoperative settings: As the patient is taken into the operating room, electrocardiography (ECG), non-invasive blood pressure (NIBP), pulse oximetry will be used, and IV line will be inserted. Baseline parameters such as systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), heart rate (HR), and oxygen saturation (SpO2) will be recorded. For all patients, anaesthesia will be induced using Propofol (2 mg/kg IV), Fentanyl (2 μg/kg IV), then patient will be intubated facilitated with Rocuronium (0.5 mg/kg IV) and the patient will be maintained on Isoflurane (1.2 - 1.5 MAC). A central venous catheter would be inserted as well as an arterial line for invasive blood pressure monitoring. End-tidal CO2 will be maintained between 25 and 30 mmHg. Fluids would be infused according to the patient's body weight with Ringer acetate through peripheral venous catheter and a fluid chart would be recorded. Patients will receive Morphine (2.5-5 mg q3-4hr PRN, infused over 4-5 minutes). The study medications will be prepared by the local pharmacy in the form of Dexmedetomidine (4 μg/ml) in a 50 mL syringe. Melatonin tablets (3 mg/tablet) would be also provided as well as placebo tablets. Then will be handled to the anaesthesiologist in charge of the patient who will be blinded to the nature of the medications used and study medications would be started 15 minutes before the end of surgical procedure. C. Postoperative settings: After extubation, patients will be taken to the ICU. During the transfer to and on arrival vital data (Blood pressure, heart rate and saturation) will be measured and recorded. The intensivist following up the patient will be blinded to the groups. Assessment of POD will be done after extubation and every 8 hours. The screening tool used to diagnose POD includes the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). D. Measurements Primary outcome: The incidence of POD after open brain surgeries. Secondary outcome 1. Time from extubation till discharge from ICU. 2. Incidence of postoperative nausea and vomiting (PONV).

Interventions

Dexmedetomidine IV Infusion at rate of (0.5 μg/kg/hr)

DRUGMelatonin

Orall Melatonin (3 mg/tablet)

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age: 30 - 60 years * Sex: Both sexes * Patients with open space occupying lesions or hematoma.

Exclusion criteria

* Refusal of the patient to give written informed consent. * History of allergy to the medications used in the study. * Psychiatric disorder. * Any form of drug addiction. * Patients receiving any anti-psychotic medications. * History of previous brain insult (Ischemic or haemorrhagic infarctions). * Pre-operative dementia. * History of malignant hyperthermia * Patient's suffering from bradycardia * Patient's suffering from hypotension

Design outcomes

Primary

MeasureTime frameDescription
The incidence of PODPerioperativelyThrough calculation of CAM-ICU Score \& RASS score of patient

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026